Daniel Billen Net Worth

The estimated Net Worth of Daniel Billen is at least $523 mil dollars as of 21 May 2024. Daniel Billen owns over 5,252 units of Aurinia Pharmaceuticals Inc stock worth over $183,761 and over the last 3 years he sold AUPH stock worth over $30,146. In addition, he makes $309,117 as Director at Aurinia Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Daniel Billen AUPH stock SEC Form 4 insiders trading

Daniel has made over 2 trades of the Aurinia Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 5,252 units of AUPH stock worth $30,146 on 21 May 2024.

The largest trade he's ever made was exercising 8,733 units of Aurinia Pharmaceuticals Inc stock on 18 May 2023 worth over $57,026. On average, Daniel trades about 3,496 units every 92 days since 2021. As of 21 May 2024 he still owns at least 28,141 units of Aurinia Pharmaceuticals Inc stock.

You can see the complete history of Daniel Billen stock trades at the bottom of the page.

Daniel Billen biography

Dr. Daniel Billen Ph.D. serves as Director of the Company. Dr. Daniel Billen has over 40 years of experience in commercialization of pharmaceutical and biotech products both in Europe and North America. He started with Janssen Pharmaceutica in their Belgian headquarters in cardiovascular global marketing in 1979. Dr. Billen became head of marketing and sales for Janssen Pharmaceutica’s newly formed affiliate in Canada in 1983 launching multiple products into the Canadian market. In 1991, Dr. Billen moved over to Amgen Inc. to lead its Canadian operations as their first General Manager. He moved to Amgen’s headquarters in California in 2011 where he led the U.S. Commercial Operations Business Unit and later the combined Nephrology and Inflammation business unit as their VP/GM. In 2017, Dr. Billen took on the role of VP of Global Commercial initiatives with focus on the evolving US payer landscape. Dr. Billen received his PhD in chemistry from the University of Louvain in Belgium.

What is the salary of Daniel Billen?

As the Director of Aurinia Pharmaceuticals Inc, the total compensation of Daniel Billen at Aurinia Pharmaceuticals Inc is $309,117. There are 10 executives at Aurinia Pharmaceuticals Inc getting paid more, with Peter Greenleaf having the highest compensation of $1,678,600.

How old is Daniel Billen?

Daniel Billen is 66, he's been the Director of Aurinia Pharmaceuticals Inc since 2019. There are 3 older and 12 younger executives at Aurinia Pharmaceuticals Inc. The oldest executive at Aurinia Pharmaceuticals Inc is George Milne, 76, who is the Independent Chairman of the Board.

What's Daniel Billen's mailing address?

Daniel's mailing address filed with the SEC is #140, 14315 - 118 AVENUE, , EDMONTON, A0, T5L 4S6.

Insiders trading at Aurinia Pharmaceuticals Inc

Over the last 4 years, insiders at Aurinia Pharmaceuticals Inc have traded over $22,019,765 worth of Aurinia Pharmaceuticals Inc stock and bought 107,125 units worth $893,295 . The most active insiders traders include Timothy P Walbert, Michael R Hayden, eMichael Robert Martin. On average, Aurinia Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $193,451. The most recent stock trade was executed by Scott Michael Habig on 6 August 2024, trading 18,249 units of AUPH stock currently worth $96,902.

What does Aurinia Pharmaceuticals Inc do?

aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.

Complete history of Daniel Billen stock trades at Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc executives and stock owners

Aurinia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Peter Greenleaf,
  President, Chief Executive Officer, Director
• Peter S. Greenleaf M.B.A.,
  Pres, CEO & Director
• Maxwell Donley,
  Executive Vice President, Internal Operations & Strategy
• Neil Solomons,
  Chief Marketing Officer
• Massimiliano Colao,
  Chief Commercial Officer
• Robert Huizinga,
  Executive Vice President - Corporate Development
• Matthew Maxwell Donley M.B.A.,
  Exec. VP of Operations & Strategy
• Joseph M. Miller CPA,
  Chief Financial Officer
• Dennis Bourgeault,
  Chief Financial Officer
• Michael Martin,
  Chief Operating Officer
• Daniel Billen,
  Director
• George Milne,
  Independent Chairman of the Board
• Michael Hayden,
  Independent Director
• Stephen P. Robertson,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Joseph Hagan,
  Independent Director
• David Jayne,
  Independent Director
• R. Hector MacKay-Dunn,
  Director
• Jill Leversage,
  Independent Director
• Stephen Robertson,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Timothy Walbert,
  Independent Director
• Max Colao,
  Chief Commercial Officer
• Tim Hermes,
  Vice President of Market Access
• Cara Felish,
  Vice President of Commercial Operations
• Chris Hays,
  Vice President of Marketing
• Fran Lynch,
  Vice President of Sales
• Glenn Schulman,
  Senior Vice President - Corporate Communications and Investor Relations
• Michael R. Martin,
  Chief Bus. Officer
• Dr. Robert B. Huizinga M.Sc., Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C),
  Exec. VP of Research
• Scott Michael Habig,
  Chief Commercial Officer
• Volker Knappertz,
  EVP, Research and Development
• Joseph M Miller,
  Chief Financial Officer
• Brinda Balakrishnan,
  Director
• Robert T Foster,
  Director
• Massimilano Colao,
  Chief Commercial Officer
• Jeffrey Allen Bailey,
  Director
• Karen L. Smith,
  Director